论文部分内容阅读
筛选66例符合入选标准的2型糖尿病肥胖患者,在继续服用二甲双胍缓释片0.5g bid基础上联合利拉鲁肽0.6~1.8 mg皮下注射qd,治疗随访观察3个月,比较治疗前后空腹血糖(FPG)、餐后2小时血糖(2h PG)、糖化血红蛋白(Hb A1c)、体重指数(BMI)、腰围、C肽变化,观察并记录其不良反应。结果:对采用利拉鲁肽联合二甲双胍缓释片治疗患者前后的空腹血糖、餐后2小时血糖、糖化血红蛋白、BMI相比较,其差异是有统计学意义(P<0.05),观察到部分患者1周内出现不良胃肠道反应,但能耐受,能自行缓解。结论:利拉鲁肽联合二甲双胍缓释片治疗能有效降低血糖,降低体重,改善BMI,不良反应轻,低血糖风险小,值得临床推广。
Sixty-six obese patients with type 2 diabetes mellitus who met the inclusion criteria were screened. On the basis of 0.5g bid of metformin sustained-release tablets and 0.6-6.8 mg liraglutide subcutaneously qd, the patients were followed up for 3 months. The fasting blood glucose (2h PG), Hb A1c, body mass index (BMI), waist circumference and C-peptide were measured. The adverse reactions were observed and recorded. Results: There was a significant difference (P <0.05) in fasting blood glucose, 2-hour postprandial blood glucose, glycosylated hemoglobin, and BMI before and after treatment with liraglutide plus metformin sustained-release tablets. Some patients were observed 1 week adverse gastrointestinal reactions, but can tolerate, to ease themselves. Conclusion: The combination of liraglutide and metformin sustained release tablets can effectively reduce blood sugar, reduce body weight, improve BMI, adverse reactions, low risk of hypoglycemia, worthy of clinical promotion.